Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
ID: 337099Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337099

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 grant mechanism. This initiative aims to support exploratory and developmental research that introduces innovative models, tests, and techniques to enhance understanding and treatment of AD/ADRD, with a focus on high-priority topics to be defined in future notices. The grant allows a diverse range of organizations, including universities, non-profits, and tribal governments, to apply for funding, with a budget cap of $275,000 for each two-year project and a maximum direct cost of $200,000 in any single year. Interested applicants should note that the application deadline is November 12, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-094-Full-Announcement.html
    PAR-22-094.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) for research on Alzheimer's Disease (AD) and its related dementias (ADRD). This specific grant, coded R21, aims to support exploratory and developmental research that introduces innovative models, tests, and techniques to advance understanding and treatment of AD/ADRD. Applications are encouraged to focus on high-priority topics, which will be defined in subsequent notices. The announcement outlines eligibility criteria, allowing a range of organizations including universities, non-profits, and state and local governments to apply. The budget for each two-year project is capped at $275,000, with a maximum direct cost of $200,000 in any one year. Key dates for application submission span from February 2022 to November 2024, with specific review cycles. The FOA emphasizes the importance of interdisciplinary research, aligning with the goals of the National Alzheimer's Project Act to combat the growing public health crisis posed by AD and ADRD, projected to significantly impact healthcare costs and demographics in the coming years.
    Similar Opportunities
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" grant, aimed at advancing research on Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity seeks to support high-priority research initiatives that address the growing public health crisis posed by these conditions, particularly among older adults. Eligible applicants include a diverse range of entities such as educational institutions, non-profits, and tribal governments, with funding decisions based on the scientific merit of proposals and the qualifications of the investigators. Applications are due by November 12, 2024, and interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting research grant applications for the "Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline" initiative. This funding opportunity aims to collect pilot data to support early-stage testing of both pharmacological and non-pharmacological interventions targeting cognitive and neuropsychiatric changes associated with Alzheimer's Disease (AD) and related dementias (ADRD). The initiative is crucial in addressing the public health crisis posed by these conditions, emphasizing the need for effective therapies and improved trial designs. Interested applicants can apply for grants with an award ceiling of $325,000, with applications due by November 18, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html.
    Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Functional Target Validation for Alzheimer’s Disease-Related Dementias (ADRD) through a phased R61/R33 grant program. This initiative aims to support the comprehensive functional validation of therapeutic target candidates identified via genetic or tissue analysis in human samples, with a focus on developing technologies and models to assess their effects. The program is critical in addressing the urgent need for novel therapeutic strategies for ADRD, which includes disorders such as frontotemporal degeneration and vascular contributions to cognitive impairment. Interested applicants, including academic institutions and community-based organizations, must submit their proposals by November 8, 2024, and can find further details at the NIH grants website or contact grantsinfo@nih.gov for inquiries.